Massey doctor honored by the American Society for Radiation Oncology
Massey physician Leland Rogers, M.D., was recently awarded the Fellows designation by the American Society for Radiation Oncology (ASTRO) at the society’s 57th Annual Meeting on October 20 in San Antonio, TX.
VCU Massey welcomes new lymphedema specialist Meagan Kirby
Beginning late November, Meagan Kirby will begin treating patients for lymphedema at Virginia Commonwealth University Massey Cancer Center. Kirby is an occupational therapist mentoring under Kim Ericson, a physical therapist who has been treating lymphedema patients in the Richmond area for 10 years. Both Kirby and Ericson received their certification in Complete Decongestive Therapy (CDT) from the Norton School of Lymphatic Therapy, making them two of only a handful of certified lymphedema specialists in the Richmond area.
New drug combination in preclinical laboratory studies effectively kills brain and breast cancer, and inhibits Ebola, influenza and many other viruses and superbug bacteria
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a drug combination that kills brain and breast cancer stem cells in preclinical laboratory studies. The breakthrough drug combination also prevents viruses, including Ebola, from replicating and makes “superbug” bacteria vulnerable to common antibiotics. The combination works by targeting a protein known as GRP78, according to a study published in the Journal of Cellular Physiology.
Massey clinical researcher receives leadership award from the National Cancer Institute
The National Cancer Institute (NCI) recently awarded a Cancer Clinical Investigator Team Leadership Award (CCITLA) to VCU Massey Cancer Center oncologist and cancer researcher Andrew Poklepovic, M.D. The CCITLA recognizes and supports outstanding mid-career clinical investigators at NCI-designated cancer centers whose leadership, participation and activities help promote cancer research through clinical trials.
Pre-clinical study shows potential to increase the effectiveness of leukemia treatments by blocking the production of a nuclear protein that affects chemotherapy response and tumor initiation
Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.